Suzi Ring

Stay informed with Suzi Ring’s coverage and analysis for Fortune.

Page 2 of 2

  • A logo at the Sanofi campus in the Gentilly district in Paris, France, on Thursday, Jan. 28, 2021. Sanofi agreed to produce millions of doses of BioNTech SE and Pfizer Inc.’s coronavirus vaccine in an unusual collaboration to speed vaccination efforts. Photographer: Nathan Laine/Bloomberg via Getty ImagesHealth

    Sanofi and GSK to restart trial of COVID-19 vaccine after delay

    By Tim Loh, Suzi Ring, and others
  • A health technician fills up a syringe with a dose of the AstraZeneca Covid-19 vaccine on the first day of the security forces inoculation at the Conde de Lippe military barracks in Lisbon, Portugal, on February 13, 2021. (Photo by Pedro Fiúza/NurPhoto via Getty Images)Health

    University of Oxford to begin testing AstraZeneca vaccine on children

    By Suzi Ring and Bloomberg
  • Nurses at the Royal Free Hospital, London, simulate the administration of the Pfizer vaccine to support staff training ahead of the rollout, which begins tomorrow. Wire photography: Yui Mok – WPA Pool—Getty ImagesInternational

    Britons will roll up their sleeves on Tuesday for a COVID vaccine jab as the world anxiously watches

    By James Paton, Suzi Ring, and others
  • Syringe shown against the AstraZeneca logoHealth

    AstraZeneca eyes another global trial for its COVID vaccine following dosage blip

    By Suzi Ring, James Paton, and others
  • A laboratory technician supervises capped vials during filling and packaging tests for the large-scale production and supply of the University of Oxfords COVID-19 vaccine candidate, AZD1222, conducted on a high-performance aseptic vial filling line on September 11, 2020 at the Italian biologics manufacturing facility of multinational corporation Catalent in Anagni, southeast of Rome, during the COVID-19 infection, caused by the novel coronavirus. – Catalent Biologics manufacturing facility in Anagni, Italy will serve as the launch facility for the large-scale production and supply of the University of Oxfords Covid-19 vaccine candidate, AZD1222, providing large-scale vial filling and packaging to British-Swedish multinational pharmaceutical and biopharmaceutical company AstraZeneca. (Photo by Vincenzo PINTO / AFP) (Photo by VINCENZO PINTO/AFP via Getty Images)Health

    Oxford says COVID-19 vaccine has produced strong immune response ahead of late-stage trial results

    By James Paton, Suzi Ring, and others
  • Researchers continue to puzzle over why the COVID vaccine developed by AstraZeneca and Oxford University appears to be more effective on a half dose. Wire photography: Lisa Maree Williams—Getty ImagesHealth

    AstraZeneca-Oxford COVID vaccine on track for year end, CEO Pascal Soriot says

    By Suzi Ring, James Paton, and others
  • Sanofi will combine its experimental coronavirus vaccine with GlaxoSmithKline Plc’s adjuvant technology, which may allow more doses of a shot to be produced.Health

    Sanofi and GlaxoSmithKline are teaming up to develop a coronavirus vaccine

    By James Paton, Suzi Ring, and others